Prolymphocytic Leukemia

hematologic malignancy

Identifier: CI-CAN-00003763
Entity page: /cancer/prolymphocytic-leukemia ↗
Edges: 157

Neighbours: 24 drugs10 trials
Drawn: 34 of 34 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,147 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Prolymphocytic Leukemia investigated for …INVESTIGATED_FOR16 of 16show fewer
← investigated for	Tafasitamabmonoclonal_antibody	unknown	2	Prolymphocytic Leukemia	1	Curated	chembl	graph →
← investigated for	Rituximabmonoclonal_antibody	unknown	2

Prolymphocytic Leukemia investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 46show all (up to 200)
→ investigated in trials for	Fludarabinesmall molecule 26 trials (4 active) · roll-up of the cancer and its descendants	—	—	Prolymphocytic Leukemia	26	Observed	clinicaltrials	graph →
→ investigated in trials for	Cyclophosphamidesmall_molecule 18 trials (4 active) · roll-up of the cancer and its descendants	—	—	Prolymphocytic Leukemia	18	Observed	clinicaltrials	graph →
→ investigated in trials for	Rituximabmonoclonal_antibody 8 trials (1 active) · roll-up of the cancer and its descendants	—	—	Prolymphocytic Leukemia	8	Observed	clinicaltrials	graph →
→ investigated in trials for	Ibrutinibsmall_molecule 7 trials (3 active) · roll-up of the cancer and its descendants	—	—	Prolymphocytic Leukemia	7	Observed	clinicaltrials	graph →
→ investigated in trials for	Lenalidomidesmall_molecule 5 trials (0 active) · roll-up of the cancer and its descendants	—	—	Prolymphocytic Leukemia	5	Observed	clinicaltrials	graph →
→ investigated in trials for	Alemtuzumabmonoclonal_antibody 4 trials (0 active) · roll-up of the cancer and its descendants	—	—	Prolymphocytic Leukemia	4	Observed	clinicaltrials	graph →
→ investigated in trials for	Sirolimussmall molecule 4 trials (0 active) · roll-up of the cancer and its descendants	—	—	Prolymphocytic Leukemia	4	Observed	clinicaltrials	graph →
→ investigated in trials for	Venetoclaxsmall_molecule 4 trials (2 active) · roll-up of the cancer and its descendants	—	—	Prolymphocytic Leukemia	4	Observed	clinicaltrials	graph →
→ investigated in trials for	Alvocidibsmall_molecule 3 trials (0 active) · roll-up of the cancer and its descendants	—	—	Prolymphocytic Leukemia	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Busulfansmall molecule 3 trials (0 active) · roll-up of the cancer and its descendants	—	—	Prolymphocytic Leukemia	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Cytarabinesmall molecule 3 trials (0 active) · roll-up of the cancer and its descendants	—	—	Prolymphocytic Leukemia	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Etoposidesmall molecule 3 trials (1 active) · roll-up of the cancer and its descendants	—	—	Prolymphocytic Leukemia	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Filgrastimother 3 trials (1 active) · roll-up of the cancer and its descendants	—	—	Prolymphocytic Leukemia	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Melphalansmall molecule 3 trials (0 active) · roll-up of the cancer and its descendants	—	—	Prolymphocytic Leukemia	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Ruxolitinibsmall molecule 3 trials (3 active) · roll-up of the cancer and its descendants	—	—	Prolymphocytic Leukemia	3	Observed	clinicaltrials	graph →

Prolymphocytic Leukemia investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 46show all (up to 200)

→ investigated in trials for

Fludarabinesmall molecule

26 trials (4 active) · roll-up of the cancer and its descendants

—

Prolymphocytic Leukemia

Observed

Prolymphocytic Leukemia studied in …STUDIED_INderived10 of 95show all (up to 200)
→ studied in	NCT05010005Phase 1 · recruiting A Study of Ruxolitinib and Duvelisib in People With Lymphoma · condition mapped ONTOLOGY_EXACT · 95 trials mapped (20 active)	—	—	T-Cell Prolymphocytic Leukemia	1	Observed	clinicaltrials	graph →
→ studied in	NCT07311746Phase 1/Phase 2 · recruiting Phase Ib/II Trial of Cladribine/Ruxolitinib/Venetoclax in Patients With Relapsed/Refractory T-cell Prolymphocytic Leukemia · condition mapped ONTOLOGY_EXACT · 95 trials mapped (20 active)	—	—	T-Cell Prolymphocytic Leukemia	1	Observed	clinicaltrials	graph →
→ studied in	NCT05377827Phase 1 · suspended Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies · condition mapped ONTOLOGY_EXACT · 95 trials mapped (20 active)	—	—	T-Cell Prolymphocytic Leukemia	1	Observed	clinicaltrials	graph →
→ studied in	NCT06810778Phase 1/Phase 2 · recruiting Duvelisib and Venetoclax in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) · condition mapped ONTOLOGY_EXACT · 95 trials mapped (20 active)	—	—	T-Cell Prolymphocytic Leukemia	1	Observed	clinicaltrials	graph →
→ studied in	NCT05805605Phase 2 · recruiting Allo HSCT Using RIC and PTCy for Hematological Diseases · condition mapped ONTOLOGY_EXACT · 95 trials mapped (20 active)	—	—	Prolymphocytic Leukemia	1	Observed	clinicaltrials	graph →
→ studied in	NCT04411043recruiting Observatory of Prolymphocytic Leukemia T · condition mapped ONTOLOGY_EXACT · 95 trials mapped (20 active)	—	—	Prolymphocytic Leukemia	1	Observed	clinicaltrials	graph →
→ studied in	NCT03314974Phase 2 · recruiting Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders · condition mapped ONTOLOGY_EXACT · 95 trials mapped (20 active)	—	—	Prolymphocytic Leukemia	1	Observed	clinicaltrials	graph →
→ studied in	NCT02007044Phase 2 · active not recruiting Ibrutinib With or Without Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia · condition mapped ONTOLOGY_EXACT · 95 trials mapped (20 active)	—	—	Prolymphocytic Leukemia	1	Observed	clinicaltrials	graph →
→ studied in	NCT04195633Phase 2 · recruiting Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies · condition mapped ONTOLOGY_EXACT · 95 trials mapped (20 active)	—	—	Prolymphocytic Leukemia	1	Observed	clinicaltrials	graph →
→ studied in	NCT05418088Phase 1 · recruiting Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies · condition mapped CURATED_BROADER · 95 trials mapped (20 active)	—	—	B-Cell Prolymphocytic Leukemia	1	Observed	clinicaltrials	graph →

Radial view

Every edge, grouped by relationship

Strongest chains